A single-centre study published in the Journal of Invasive Cardiology noted that treatment with Cardiac Dimensions’ Carillon mitral contour system resulted in significant improvement of functional mitral regurgitation (FMR).
The Carillon device is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, using standard interventional techniques, according to a company release. Through multiple clinical trials, the device has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life.
Researchers in this study noted that percutaneous treatment for FMR is clinically valuable due to the widespread prevalence of the problem and the lack of alternative available therapies.
“In this ‘real-life’ setting, we observed a marked reduction in FMR and continued improvement in the condition over time, with the majority of patients experiencing clinical success similar to the results of the TITAN Trial,” says Norbert Klein, Department of Cardiology and Angiology, University Hospital Leipzig, Leipzig, Germany, and lead author of the study. “In addition, we experienced short procedure times, ease of implantation and compatibility with other cardiac therapies.”
Data were collected from a prospective, single-centre, non-randomised observational analysis of 17 consecutive patients with moderate-to-severe FMR, despite stable optimal medical drug treatment. Patients were selected for percutaneous rather than surgical approach due to high surgical risk as assessed by the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and the Society of Thoracic Surgeons (STS) score.
